Faeth Therapeutics sits below the platform's quality floor on cash-burn and Piotroski weakness, but extreme short interest and a wide analyst-implied upside create an asymmetric speculative setup typical of early-stage biotech.
Thesis pillars
- Large Analyst Upside Favorable Asymmetry↓Deteriorating
- Quality Below Floor Cash Burn↓Deteriorating
- Extreme High Short Interest↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 5, 2026, based on the 10-K filed Mar 30, 2026· older than 90 days
Faeth Therapeutics, Inc. (FTH) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $7.88, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: PIKTOR; DATA_ISSUE: analyst_target_implausible (raw $56.15 vs price $7.88 — ratio 7.1×). Rejected, falling back to technical TP..
Faeth Therapeutics, Inc. (formerly Sensei Biotherapeutics) is a clinical-stage biotechnology company developing PIKTOR, an oral multi-node inhibitor of the PI3K/AKT/mTOR pathway, for endometrial and HR+/HER2- breast cancer, following its February 2026 acquisition of Faeth... Read more
Hold if already holding. Not a fresh buy at $7.88, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: PIKTOR; DATA_ISSUE: analyst_target_implausible (raw $56.15 vs price $7.88 — ratio 7.1×). Rejected, falling back to technical TP.. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $204M below $400M minimum. Not in investable universe. Score 4.5/10, moderate confidence.
Passes 5/8 gates (clean insider activity, news events none recent, earnings proximity 87d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
About Faeth Therapeutics, Inc.
About Faeth Therapeutics, Inc.
PIKTOR, Faeth Therapeutics' lead oral multi-node PI3K/AKT/mTOR pathway inhibitor, is being evaluated in an ongoing Phase 2 trial in second-line advanced endometrial cancer (FTH-PIK-201), with topline data expected by year-end 2026, following the company's February 2026 acquisition of Faeth Therapeutics and a concurrent $200 million private placement. The company, formerly Sensei Biotherapeutics, reported a net loss of $21.1 million in 2025 and an accumulated deficit of $283.1 million, and has not generated product revenue to date.
Faeth has not generated product revenue and funds its PIKTOR development primarily through equity financings, including the $200 million private placement completed alongside the February 2026 Faeth acquisition from a syndicate that included B Group Capital, Balyasny Asset Management, Cormorant Asset Management, RA Capital Management, and Vivo Capital. PIKTOR combines two independently dosed, orally administered inhibitors -- serabelisib (a PI3Kalpha inhibitor) and sapanisertib (an mTORC1/2 inhibitor) -- designed to suppress the PI3K/AKT/mTOR pathway at multiple nodes rather than the single node targeted by the five currently approved therapies in this class. The company relies on third parties to conduct its preclinical and clinical trials and was not involved in PIKTOR's early development, making it dependent on external parties having accurately generated and reported the asset's historical data. Near-term catalysts include topline Phase 2 endometrial cancer data (FTH-PIK-201) expected by year-end 2026 and initiation of a Phase 1b breast cancer trial (FTH-PIK-101) targeted for the first half of 2026.
Show full overview
Faeth's valuation rests almost entirely on one clinical-stage asset: PIKTOR is the company's sole named product candidate advancing through active trials, and a failure of either the Phase 2 endometrial readout or the planned Phase 1b breast cancer study to demonstrate safety and efficacy to regulators' satisfaction would leave the pipeline without a near-term alternative. That binary exposure is compounded by the company's post-acquisition history: Faeth (through predecessor Sensei) was not involved in PIKTOR's early development and depends on third parties having accurately generated, collected, and reported the preclinical and clinical data underlying the program to date.
See also: Healthcare · Biotechnology
From Faeth Therapeutics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated Nov 16, 2026Recent Developments — Faeth Therapeutics, Inc.
Latest news
- NEWS Needham Reiterates Buy on Faeth Therapeutics, Maintains $56 Price Target — benzinga Nov 16, 2026
- NEWS HC Wainwright & Co. Reiterates Buy on Faeth Therapeutics, Maintains $60 Price Target — benzinga Nov 16, 2026
- NEWS Faeth Therapeutics Enters Into Clinical Trial Collaboration And Supply Agreement With Roche To Evaluate PIKTOR In Combin — benzinga Nov 16, 2026
- NEWS Citigroup Maintains Buy on Faeth Therapeutics, Raises Price Target to $60 — benzinga Nov 10, 2026
- NEWS Crude Oil Falls Over 3%; NRG Energy Shares Jump After Strong Q3 Results — benzinga Nov 9, 2026
Latest item Nov 16, 2026 · Generated 2026-11-22T12:07:32Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinePIKTOR10-K Item 1: 'Following the Acquisition, our lead program is PIKTOR, an investigational multi-node inhibitor, or MNI, of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer'
Material Events(8-K, last 90d)
- 2026-06-15Item 5.02MEDIUMThe Board appointed Anand Parikh, currently the Company's Chief Operating Officer, as President and Chief Executive Officer effective June 13, 2026. No prior CEO departure reason cited in the excerpt provided.SEC filing →
- 2026-06-15Item 1.02LOWOn June 10, 2026, the Company terminated its 2022 at-the-market Sales Agreement with Jefferies LLC (up to $50 million), effective immediately; no shares were ever sold under the agreement prior to termination.SEC filing →
- 2026-04-16Item 5.02MEDIUMDirectors Christopher W. Gerry, Thomas Ricks, and Kristian Humer tendered conditional resignations effective two business days after the June 10, 2026 Annual Meeting, contingent on stockholder approval of a Series B preferred conversion (resulting in a Nasdaq change-of-control) and a charter amendment raising authorized shares from 12,500,000 to 300,000,000.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 28.1% daily ATR makes tight stops impractical. Position-size conservatively.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $7.88, but acceptable to hold if already in. Reasons: Concentration risk — Pipeline: PIKTOR; DATA_ISSUE: analyst_target_implausible (raw $56.15 vs price $7.88 — ratio 7.1×). Rejected, falling back to technical TP.. Chart setup: No clear chart pattern; technical signals are mixed. Market cap $204M below $400M minimum. Not in investable universe. Resistance target $21.61 (+174.2%), stop $7.60 (−3.7%), A.R:R 0.0:1. Score 4.5/10, moderate confidence.
Resistance target: $21.61 (+174.2% upside). Resistance target $21.61 (+174.2%), stop $7.60 (−3.7%), A.R:R 0.0:1. Stop-loss: $7.60.
Concentration risk — Pipeline: PIKTOR; DATA_ISSUE: analyst_target_implausible (raw $56.15 vs price $7.88 — ratio 7.1×). Rejected, falling back to technical TP.; Market cap $204M below $400M minimum.
Faeth Therapeutics, Inc. trades at a P/E of N/A (forward -2.1). TrendMatrix value score: 5.0/10. Verdict: Hold.
19 analysts rate FTH, with a consensus score of 4.3/5. 13 analysts publish price targets averaging $56.
What does Faeth Therapeutics, Inc. do?Faeth Therapeutics, Inc. (formerly Sensei Biotherapeutics) is a clinical-stage biotechnology company developing PIKTOR,...
Faeth Therapeutics, Inc. (formerly Sensei Biotherapeutics) is a clinical-stage biotechnology company developing PIKTOR, an oral multi-node inhibitor of the PI3K/AKT/mTOR pathway, for endometrial and HR+/HER2- breast cancer, following its February 2026 acquisition of Faeth Therapeutics. The company raised $200 million in gross proceeds from a concurrent private placement, reported a net loss of $21.1 million in 2025 and an accumulated deficit of $283.1 million, and has not generated product revenue.